vs
Side-by-side financial comparison of Bio-Techne (TECH) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $257.2M, roughly 1.2× WESBANCO INC). WESBANCO INC runs the higher net margin — 34.5% vs 12.8%, a 21.6% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs 4.2%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
TECH vs WSBC — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $257.2M |
| Net Profit | $38.0M | $88.6M |
| Gross Margin | 64.6% | — |
| Operating Margin | 18.4% | — |
| Net Margin | 12.8% | 34.5% |
| Revenue YoY | -6.4% | — |
| Net Profit YoY | 68.3% | 54.4% |
| EPS (diluted) | $0.24 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $295.9M | $265.6M | ||
| Q3 25 | — | $261.6M | ||
| Q2 25 | $317.0M | $260.7M | ||
| Q1 25 | $316.2M | $193.2M | ||
| Q4 24 | $297.0M | $162.9M | ||
| Q3 24 | $289.5M | $150.8M | ||
| Q2 24 | $306.1M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $38.0M | $91.1M | ||
| Q3 25 | — | $83.6M | ||
| Q2 25 | $-17.7M | $57.4M | ||
| Q1 25 | $22.6M | $-9.0M | ||
| Q4 24 | $34.9M | $49.6M | ||
| Q3 24 | $33.6M | $37.3M | ||
| Q2 24 | $40.6M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 62.7% | — | ||
| Q1 25 | 67.9% | — | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | — | ||
| Q2 24 | 66.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 18.4% | 43.2% | ||
| Q3 25 | — | 39.5% | ||
| Q2 25 | -7.5% | 27.2% | ||
| Q1 25 | 12.2% | -5.0% | ||
| Q4 24 | 16.0% | 38.0% | ||
| Q3 24 | 13.8% | 29.7% | ||
| Q2 24 | 15.0% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | 12.8% | 34.3% | ||
| Q3 25 | — | 31.9% | ||
| Q2 25 | -5.6% | 22.0% | ||
| Q1 25 | 7.1% | -4.7% | ||
| Q4 24 | 11.7% | 30.5% | ||
| Q3 24 | 11.6% | 24.7% | ||
| Q2 24 | 13.3% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.24 | $0.97 | ||
| Q3 25 | — | $0.84 | ||
| Q2 25 | $-0.11 | $0.57 | ||
| Q1 25 | $0.14 | $-0.15 | ||
| Q4 24 | $0.22 | $0.72 | ||
| Q3 24 | $0.21 | $0.54 | ||
| Q2 24 | $0.26 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | — |
| Total DebtLower is stronger | $260.0M | — |
| Stockholders' EquityBook value | $2.0B | $4.1B |
| Total Assets | $2.5B | $27.5B |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $172.9M | $956.1M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | $162.2M | $1.2B | ||
| Q1 25 | $140.7M | $1.1B | ||
| Q4 24 | $177.5M | $568.1M | ||
| Q3 24 | $187.5M | $620.9M | ||
| Q2 24 | $152.9M | $486.8M |
| Q1 26 | — | — | ||
| Q4 25 | $260.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $346.0M | — | ||
| Q1 25 | $330.0M | — | ||
| Q4 24 | $300.0M | — | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $2.0B | $4.0B | ||
| Q3 25 | — | $4.1B | ||
| Q2 25 | $1.9B | $3.8B | ||
| Q1 25 | $2.0B | $3.8B | ||
| Q4 24 | $2.1B | $2.8B | ||
| Q3 24 | $2.1B | $2.8B | ||
| Q2 24 | $2.1B | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $2.5B | $27.7B | ||
| Q3 25 | — | $27.5B | ||
| Q2 25 | $2.6B | $27.6B | ||
| Q1 25 | $2.6B | $27.4B | ||
| Q4 24 | $2.7B | $18.7B | ||
| Q3 24 | $2.7B | $18.5B | ||
| Q2 24 | $2.7B | $18.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
